PUR001’s Innovative Antitumor Activity Differentiate from Other CD39-targeted Drugs, which includes a mechanism-of-action resulting in massive tumor necrosis and immunogenic cell death, leading to increased activation of antitumor immune responses.
Unlike all of the other clinical anti-CD39 antibodies, PUR001 uniquely offers the opportunity to have monotherapy efficacy, as well as synergism with other I/O agents and with chemotherapies.
Collaborated with global strategic partners,
Purinomia expanded its clinical operation to different regions beyond US market.
Purinomia has a robust, proprietary pipeline that is strategically designed to target high unmet needs – oncology and inflammatory diseases.